Skip to main navigation Skip to search Skip to main content

Prolonged Treatment with Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL),

  • Andres Forero-Torres
  • , R. Brian Berryman
  • , Ranjana H. Advani
  • , Nancy L. Bartlett
  • , Robert W. Chen
  • , Michelle A. Fanale
  • , Ajay K. Gopal
  • , Owen A. O'Connor
  • , Randal Olshefski
  • , Scott E. Smith
  • , Laurie E. Grove
  • , Jeffrey Matous
  • University of Alabama at Birmingham
  • Baylor University Medical Center
  • Stanford University
  • Washington University in St. Louis
  • City of Hope National Medical Center
  • University of Texas MD Anderson Cancer Center
  • University of Washington Medical Center
  • New York University
  • Nationwide Children's Hospital
  • Loyola University Chicago
  • Seattle Genetics
  • Colorado Blood Cancer Institute, Denver, CO, USA.

Research output: Contribution to journalArticlepeer-review

Original languageAmerican English
JournalBlood
Volume118
Issue number21
DOIs
StatePublished - Nov 18 2011
Externally publishedYes

Disciplines

  • Immunology and Infectious Disease
  • Medicine and Health Sciences
  • Internal Medicine

Cite this